GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)

GenSight Biologics Announces the Filing of its 2018 Annual Financial Report

GenSight Biologics announces presentation of 72-week data from the REVERSE & RESCUE Phase III trials of GS010 at the Annual Meeting of ARVO

GenSight Biologics Reports Full Year 2018 Financial Results

GenSight Biologics Reports its Cash Position as of March 31, 2019

GenSight Biologics reports positive follow-up results at Week 72 of the RESCUE Phase III clinical trial of GS010 in Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the 45th annual meeting of NANOS

GenSight Biologics completes a capital increase of €8 million without discount subscribed entirely by Sofinnova

GenSight Biologics announces publication of positive safety data from Phase I/II trial of GS010 in the JAMA Ophthalmology

GenSight Biologics reports topline results at Week 48 of the RESCUE Phase III clinical trial of GS010 in subjects within six months of visual loss onset due to Leber Hereditary Optic Neuropathy (LHON)